Works by Weber, Martin S.


Results: 69
    1
    2
    3
    4
    5
    6

    Therapeutic Decisions in Multiple Sclerosis Moving Beyond Efficacy.

    Published in:
    JAMA Neurology, 2013, v. 70, n. 10, p. 1315, doi. 10.1001/jamaneurol.2013.3510
    By:
    • Brück, Wolfgang;
    • Gold, Ralf;
    • Lund, Brett T.;
    • Oreja-Guevara, Celia;
    • Prat, Alexandre;
    • Spencer, Collin M.;
    • Steinman, Lawrence;
    • Tintoré, Mar;
    • Vollmer, Timothy L.;
    • Weber, Martin S.;
    • Weiner, Leslie P.;
    • Ziemssen, Tjalf;
    • Zamvil, Scott S.
    Publication type:
    Article
    7
    8

    Immunological Aspects of Approved MS Therapeutics.

    Published in:
    Frontiers in Immunology, 2019, p. 1, doi. 10.3389/fimmu.2019.01564
    By:
    • Rommer, Paulus S.;
    • Milo, Ron;
    • Han, May H.;
    • Satyanarayan, Sammita;
    • Sellner, Johann;
    • Hauer, Larissa;
    • Illes, Zsolt;
    • Warnke, Clemens;
    • Laurent, Sarah;
    • Weber, Martin S.;
    • Zhang, Yinan;
    • Stuve, Olaf
    Publication type:
    Article
    9
    10

    Pharmacological Treatment of Early Multiple Sclerosis.

    Published in:
    Drugs, 2008, v. 68, n. 1, p. 73, doi. 10.2165/00003495-200868010-00005
    By:
    • Stüve, Olaf;
    • Bennett, Jeffrey L.;
    • Hemmer, Bernhard;
    • Wiendl, Heinz;
    • Racke, Michael K.;
    • Bar-Or, Amit;
    • Wei Hu;
    • Zivadinov, Robert;
    • Weber, Martin S.;
    • Zamvil, Scott S.;
    • Pacheco, Maria F.;
    • Menge, Til;
    • Hartung, Hans-Peter;
    • Kieseier, Bernd C.;
    • Frohman, Elliot M.
    Publication type:
    Article
    11
    12
    13
    14
    15

    Diagnostik und Therapie von Tuberkulose unter Immuntherapien für Multiple Sklerose: Aktueller Stand und Empfehlungen in Deutschland.

    Published in:
    Der Nervenarzt, 2019, v. 90, n. 12, p. 1245, doi. 10.1007/s00115-019-0760-0
    By:
    • Bittner, Stefan;
    • Engel, Sinah;
    • Lange, Christoph;
    • Weber, Martin S.;
    • Haghikia, Aiden;
    • Luessi, Felix;
    • Korn, Thomas;
    • Klotz, Luisa;
    • Bayas, Antonios;
    • Paul, Friedemann;
    • Heesen, Christoph;
    • Stangel, Martin;
    • Wildemann, Brigitte;
    • Bergh, Florian Then;
    • Tackenberg, Björn;
    • Trebst, Corinna;
    • Warnke, Clemens;
    • Linker, Ralf;
    • Kerschensteiner, Martin;
    • Zettl, Uwe
    Publication type:
    Article
    16
    17
    18

    Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.

    Published in:
    Multiple Sclerosis Journal, 2024, v. 30, n. 4/5, p. 558, doi. 10.1177/13524585241234783
    By:
    • Montalban, Xavier;
    • Piasecka-Stryczynska, Karolina;
    • Kuhle, Jens;
    • Benkert, Pascal;
    • Arnold, Douglas L;
    • Weber, Martin S;
    • Seitzinger, Andrea;
    • Guehring, Hans;
    • Shaw, Jamie;
    • Tomic, Davorka;
    • Hyvert, Yann;
    • Harlow, Danielle E;
    • Dyroff, Martin;
    • Wolinsky, Jerry S
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.

    Published in:
    Therapeutic Advances in Neurological Disorders, 2024, p. 1, doi. 10.1177/17562864241277736
    By:
    • Derfuss, Tobias;
    • Bermel, Robert;
    • Lin, Chien-Ju;
    • Hauser, Stephen L.;
    • Kappos, Ludwig;
    • Vollmer, Timothy;
    • Comi, Giancarlo;
    • Giovannoni, Gavin;
    • Hartung, Hans-Peter;
    • Weber, Martin S.;
    • Wang, Jianmei;
    • Jessop, Nikki;
    • Chognot, Cathy;
    • Craveiro, Licinio;
    • Bar-Or, Amit
    Publication type:
    Article
    36

    Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.

    Published in:
    Therapeutic Advances in Neurological Disorders, 2024, v. 17, p. 1, doi. 10.1177/17562864241277736
    By:
    • Derfuss, Tobias;
    • Bermel, Robert;
    • Lin, Chien-Ju;
    • Hauser, Stephen L.;
    • Kappos, Ludwig;
    • Vollmer, Timothy;
    • Comi, Giancarlo;
    • Giovannoni, Gavin;
    • Hartung, Hans-Peter;
    • Weber, Martin S.;
    • Wang, Jianmei;
    • Jessop, Nikki;
    • Chognot, Cathy;
    • Craveiro, Licinio;
    • Bar-Or, Amit
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44

    Myelinosome formation represents an early stage of oligodendrocyte damage in multiple sclerosis and its animal model.

    Published in:
    Nature Communications, 2016, v. 7, n. 11, p. 13275, doi. 10.1038/ncomms13275
    By:
    • Romanelli, Elisa;
    • Merkler, Doron;
    • Mezydlo, Aleksandra;
    • Weil, Marie-Theres;
    • Weber, Martin S.;
    • Nikić, Ivana;
    • Potz, Stephanie;
    • Meinl, Edgar;
    • Matznick, Florian E. H.;
    • Kreutzfeldt, Mario;
    • Ghanem, Alexander;
    • Conzelmann, Karl-Klaus;
    • Metz, Imke;
    • Brück, Wolfgang;
    • Routh, Matthew;
    • Simons, Mikael;
    • Bishop, Derron;
    • Misgeld, Thomas;
    • Kerschensteiner, Martin
    Publication type:
    Article
    45
    46
    47
    48
    49
    50